• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Gestational Thrombocytopenia: What is the Threshold for Further Follow-Up?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Gestational thrombocytopenia is defined as platelet count < 150,000 per cubic millimeter (see ‘Related ObG Topics’, below)
  • However, data on platelet counts throughout pregnancy is limited
  • Reese et al. (NEJM, 2018) sought to determine the platelet counts in complicated and uncomplicated pregnancies to assess the occurrence and severity of thrombocytopenia throughout pregnancy

METHODS:

  • Cohort Study (2011-2014)
  • Participants
    • Women 15 to 44 years of age
  • Platelet counts were compared with those of non-pregnant women
  • Data on complications were also recorded, including those known to be associated with low platelet counts (e.g., HELLP and ITP)
  • Twins were analyzed separately
    • Preterm defined as <37 weeks in singletons and <34 weeks in twins
  • National Health and Nutrition Examination Survey (NHANES) data (nonpregnant women 15 to 44 years of age) were used for comparisons
  • Primary objectives
    • Determine change in platelet counts during pregnancy
    • Determine whether rate of decrease differed during pregnancy between women with uncomplicated pregnancies compared to pregnancy-related complications/preexisting disorders
    • Recurrence risk

RESULTS:

  • 7,351 provided sufficient data for the analyses
    • 4,568 had uncomplicated pregnancies
    • 2,586 had pregnancy-related complications
    • 197 had preexisting disorders associated with thrombocytopenia
  • Mean platelet counts in uncomplicated pregnancies were as follows
    • First trimester (mean gestation, 8.7 weeks): 251,000 per cubic millimeter
    • Second trimester (mean gestation, 22.0 weeks): 230,000 per cubic millimeter
    • Third trimester (mean gestation, 32.1 weeks): 225,000 per cubic millimeter
    • Delivery (mean gestation, 39.0 weeks): 217,000 per cubic millimeter
    • Postpartum period (mean time after delivery, 7.1 weeks): 264,000 per cubic millimeter
  • Uncomplicated pregnancies had lower platelet counts throughout pregnancy during each trimester and at delivery compared to nonpregnant women (P<0.001)
    • There was no difference in the postpartum period (P=0.10)
  • At delivery
    • 9.9% of uncomplicated pregnancies had a platelet count <150,000 per cubic millimeter
    • Platelet counts <150,000 per cubic millimeter were more common among women who had pregnancy-related complications (11.9%) than among women who had uncomplicated pregnancies (9.9%); P=0.01
  • In uncomplicated pregnancies
    • only 1% had a platelet count <100,000 per cubic millimeter
    • Only 0.1% of women with platelet counts <80,000 per cubic millimeter (median 65,000) had no explanation for their thrombocytopenia
  • In women with pregnancy-related complications
    • 2.3% of women had a platelet count <100,000 per cubic millimeter throughout pregnancy and/or delivery
    • 1.2% had a platelet count <80,000 per cubic millimeter throughout pregnancy and/or delivery
    • HELLP: 28.0% had a platelet count <80,000 per cubic millimeter (median, 61,000; range, 32,000 to 78,000)
  • Risk of recurrence was 14.2 (95% CI, 8.9 to 22.6) times as high among women who had previously had a platelet count <150,000 per cubic millimeter

CONCLUSION:

  • Mean platelet counts are lower in pregnancy throughout gestation starting in the first trimester
  • Platelet counts of less <100,000 per cubic millimeter warrants further investigation

Learn More – Primary Sources:

Platelet Counts during Pregnancy

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Gestational Thrombocytopenia – a Diagnosis of Exclusion
Fatty Liver of Pregnancy: A True Obstetric Emergency

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site